NSAIDs Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion
Loading…

Market Dynamics of NSAIDs Market Analysis

↑ Growth Drivers

  • Increasing prevalence of chronic pain disorders
  • Growing geriatric population
  • Rising demand for over-the-counter medications

↓ Restraints

  • Side effects such as gastrointestinal issues
  • High cost of branded NSAIDs

~ Trends

  • Increasing preference for combination therapies
  • Expansion of online pharmacies for better accessibility

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

NSAIDs Market Analysis — Presence

Interactive World Map

Click countries to explore
Loading map…

Regional and Country Analysis

  • North America — United States, Canada, Mexico
  • Europe — United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe
  • Asia Pacific — China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC
  • South America — Brazil, Argentina, Colombia, Peru, Chile, Rest of South America
  • Middle East — Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East
  • Africa — East Africa, West Africa, North Africa, South Africa

Region / Country 2021 (A)2025 (A)2033 (P) CAGR

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Market size by (Illustrative, 2025)
Share distribution (2025)

Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.

To learn more about market share and segmentation, request the free sample pages.

Competitive Landscape of the NSAIDs Market

The NSAIDs market is highly competitive, with numerous global players offering a wide range of products. Companies such as Pfizer, Johnson & Johnson, and Bayer dominate the market with established brands like Advil, Aleve, and Aspirin. Competition is based on factors such as product innovation, safety profiles, pricing, and distribution networks. Emerging companies are focusing on developing safer, more effective NSAID formulations, while larger companies maintain their leadership through strong brand recognition and extensive distribution channels.

In February 2024, Hikma Pharmaceuticals introduced COMBOGESIC IV in the U.S., offering an opioid-free alternative for adult pain management. COMBOGESIC IV combines acetaminophen (1,000 mg) and ibuprofen (300 mg) for intravenous use, receiving FDA approval in October 2023 for treating mild to moderate pain, with an adjunctive role in severe pain alongside opioids. This dual-action solution aligns with the American Society of Anesthesiology’s multimodal pain management strategy, offering quicker and sustained pain relief. Developed by AFT Pharmaceuticals, COMBOGESIC IV is also marketed globally as MAXIGESIC IV. (Source: https://www.hikma.com/news/hikma-announces-us-launch-of-combogesic-iv/) In December 2023, Scilex Holding Company submitted a New Drug Submission to Health Canada for ELYXYB (celecoxib oral solution), intended to treat acute migraines. ELYXYB is the only FDA-approved oral solution for migraines, offering pain relief within 15 minutes. With the Canadian migraine therapeutics market expected to reach USD 400 million by 2025, Scilex anticipates approval within a year. The company aims to provide an alternative for patients who are not responsive to triptan therapies. (Source: https://scilexholding.gcs-web.com/news-releases/news-release-details/scilex-holding-company-announces-filing-new-drug-submission-nds)

Click any bar or cell to request the full company profile
Company2022 (A)2023 (A)2024 (A)2025 (A)
Pfizer Inc.••• ••• ••• •••
Johnson & Johnson••• ••• ••• •••
Novartis AG••• ••• ••• •••
GlaxoSmithKline plc••• ••• ••• •••
Bayer AG••• ••• ••• •••
Sanofi S.A.••• ••• ••• •••
Abbott Laboratories••• ••• ••• •••
Merck & Co.••• ••• ••• •••
Inc.••• ••• ••• •••
Amgen Inc.••• ••• ••• •••
Mylan N.V.••• ••• ••• •••
Teva Pharmaceutical Industries Ltd.••• ••• ••• •••
Aurobindo Pharma••• ••• ••• •••
Cipla Limited••• ••• ••• •••
Sun Pharmaceutical Industries Ltd.••• ••• ••• •••
Mallinckrodt Pharmaceuticals••• ••• ••• •••

Revenue data requires full access. *2nd & 3rd tier companies available on enquiry.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, the global NSAIDs market size was USD 18542.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.50% from 2024 to 2031.

  • North America held the major market share for more than 40% of the global revenue with a market size of USD 7417.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
  • Europe accounted for a market share of over 30% of the global revenue with a market size of USD 5562.75 million.
  • Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 4264.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
  • Latin America had a market share of more than 5% of the global revenue with a market size of USD 927.13 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
  • Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 370.85 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
  • The aspirin is the fastest growing segment of the NSAIDs industry

 

Introduction of the NSAIDs Market

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are widely used medications to alleviate pain, reduce inflammation, and lower fever. These drugs work by inhibiting cyclooxygenase (COX) enzymes, which are responsible for the production of prostaglandins, substances involved in inflammation. NSAIDs are available in various types, including aspirin, ibuprofen, naproxen, and nabumetone, each with distinct pharmacological profiles. They are prescribed for a variety of conditions, such as arthritis, migraine, and ophthalmic diseases. NSAIDs can be administered orally, topically, or via other routes, and they are distributed through hospital pharmacies, retail pharmacies, and online platforms.

In April 2024, Glenmark Pharmaceuticals received approval from the U.S. FDA for its Acetaminophen and Ibuprofen Tablets (250 mg/125 mg), which will be sold as an over-the-counter product. This formulation is bioequivalent to Haleon’s Advil Dual Action with Acetaminophen, which earned approximately USD 84.1 million in sales over the past year. Glenmark plans to strengthen its portfolio with 195 approved products in the U.S. and 52 ANDAs pending. The company focuses on respiratory, dermatology, and oncology treatments and operates across 11 manufacturing facilities worldwide. (Source: https://glenmarkpharma-us.com/press/glenmark-pharmaceuticals-receives-anda-approval-for-acetaminophen-and-ibuprofen-tablets-250-mg-125-mg-otc/)

NSAIDs Market Analysis Insights Video

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The NSAIDs Market Analysis is witnessing significant growth in the near future.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst · Cognitive Market Research
LinkedIn Profile Book Appointment

Frequently Asked Questions

The global market size for NSAIDs in 2024 is USD 18542.5 million.
The global NSAIDs market is expected to grow with a CAGR of 6.50% over the projected period.
North America held a significant global NSAIDs market revenue share in 2024.
Asia-Pacific will witness the fastest growth of the global NSAIDs market over the coming years.
The US had the most significant global NSAIDs market revenue share in 2024.
The main driver of the growth of the NSAIDs market are increasing prevalence of chronic pain disorders, growing geriatric population, and rising demand for over-the-counter medications.
The osteoarthritis treatment dominates the market.

★ Reviews

Rate this report

NSAIDs Market Analysis — Table of Contents

Disclaimer: Redacted sample for representative purposes. Charts and data do not depict actual statistics. TOC varies by license selection.
License Edition

End Use Outlook: Back Pain Treatment, Osteoarthritis Treatment, Other Disease Treatment
Administration Outlook: Oral, Topical, Others
Distribution Channel Outlook: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
List of Competitors Pfizer Inc., Johnson & Johnson, Novartis AG, GlaxoSmithKline plc, Bayer AG, Sanofi S.A., Abbott Laboratories, Merck & Co., Inc., Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Cipla Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals

  • 1.1 Global Power Realignment & Strategic Alliances
  • 1.2 Geopolitical Risk Landscape & Conflict Hotspots
  • 1.3 International Trade Relations & Market Access Environment
  • 1.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
  • 1.5 Supply Chain Resilience, Localization & Resource Nationalism
  • 1.6 Technology Sovereignty & Digital Geopolitics
  • 1.7 Strategic Implications for Investment, Growth & Market Entry

  • 2.1 Competitive Landscape Disruption & Strategic Shifts
  • 2.2 AI-Driven Transformation of Industry Value Chain
  • 2.3 Evolution of Business Models & Revenue Streams
  • 2.4 Operational Efficiency & Cost Structure Transformation
  • 2.5 Product, Service & Innovation Acceleration
  • 2.6 Customer Behavior & Demand Evolution
  • 2.7 Future Outlook: AI-Led Market Evolution & Strategic Implications

  • 3.1 Global NSAIDs Revenue Market Size, Trend Analysis 2022 - 2034
  • 3.2 Global NSAIDs Volume Market Sales, Trend Analysis 2022 - 2034

  • Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

    3.3 Global NSAIDs Market Size By Regions 2022 - 2034
    • 3.3.1 Global NSAIDs Revenue Market Size By Region
    • 3.3.2 Global NSAIDs Volume Market Sales By Region
  • 3.4 Global NSAIDs Market Size By End Use Outlook: 2022 - 2034
    • 3.4.1 Back Pain Treatment Market Size
    • 3.4.2 Osteoarthritis Treatment Market Size
    • 3.4.3 Other Disease Treatment Market Size
  • 3.5 Global NSAIDs Volume Market Sales By End Use Outlook: 2022 - 2034
    • 3.5.1 Back Pain Treatment Sales Volume
    • 3.5.2 Osteoarthritis Treatment Sales Volume
    • 3.5.3 Other Disease Treatment Sales Volume
  • 3.6 Global NSAIDs Market Size By Administration Outlook: for 2022 - 2034
    • 3.6.1 Oral Market Size
    • 3.6.2 Topical Market Size
    • 3.6.3 Others Market Size
  • 3.7 Global NSAIDs Volume Market Sales By Administration Outlook: 2022 - 2034
    • 3.7.1 Oral Sales Volume
    • 3.7.2 Topical Sales Volume
    • 3.7.3 Others Sales Volume
  • 3.8 Global NSAIDs Market Size By Distribution Channel Outlook: for 2022 - 2034
    • 3.8.1 Hospital Pharmacy Market Size
    • 3.8.2 Retail Pharmacy Market Size
    • 3.8.3 Online Pharmacy Market Size
  • 3.9 Global NSAIDs Volume Market Sales By Distribution Channel Outlook: 2022 - 2034
    • 3.9.1 Hospital Pharmacy Sales Volume
    • 3.9.2 Retail Pharmacy Sales Volume
    • 3.9.3 Online Pharmacy Sales Volume
  • 3.10 Global Level Competitor Analysis (Subject to Data Availability (Private Players))

  • You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)

    3.11 Executive Summary Global Market (2021 vs 2025 vs 2033)
    • 3.11.1 Regional Market Revenue Summary 2021 vs 2025 vs 2033
    • 3.11.2 Regional Volume Market Summary 2021 vs 2025 vs 2033
    • 3.11.3 Global Market Revenue Split By End Use Outlook:
    • 3.11.4 Global Volume Market Split By End Use Outlook:
    • 3.11.5 Global Market Revenue Split By Administration Outlook:
    • 3.11.6 Global Volume Market Split By Administration Outlook:
    • 3.11.7 Global Market Revenue Split By Distribution Channel Outlook:
    • 3.11.8 Global Volume Market Split By Distribution Channel Outlook:

    • Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable

      3.11.9 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities

  • 4.1 North America NSAIDs Market Outlook
    • 4.1.1 North America NSAIDs Market Size 2022 - 2034
    • 4.1.2 North America NSAIDs Volume Market Sales 2022 - 2034
    • 4.1.3 North America NSAIDs Market Size By Country 2022 - 2034
    • 4.1.4 North America NSAIDs Volume Market Sales By Country 2022 - 2034
    • 4.1.5 North America NSAIDs Market Size by End Use Outlook: 2022 - 2034
      • 4.1.5.1 North America Back Pain Treatment Market Size
      • 4.1.5.2 North America Osteoarthritis Treatment Market Size
      • 4.1.5.3 North America Other Disease Treatment Market Size
    • 4.1.6 North America NSAIDs Volume Market Sales by End Use Outlook: 2022 - 2034
      • 4.1.6.1 North America Back Pain Treatment Sales Volume
      • 4.1.6.2 North America Osteoarthritis Treatment Sales Volume
      • 4.1.6.3 North America Other Disease Treatment Sales Volume
    • 4.1.7 North America NSAIDs Market Size by Administration Outlook: 2022 - 2034
      • 4.1.7.1 North America Oral Market Size
      • 4.1.7.2 North America Topical Market Size
      • 4.1.7.3 North America Others Market Size
    • 4.1.8 North America NSAIDs Volume Market Sales by Administration Outlook: 2022 - 2034
      • 4.1.8.1 North America Oral Sales Volume
      • 4.1.8.2 North America Topical Sales Volume
      • 4.1.8.3 North America Others Sales Volume
    • 4.1.9 North America NSAIDs Market Size by Distribution Channel Outlook: 2022 - 2034
      • 4.1.9.1 North America Hospital Pharmacy Market Size
      • 4.1.9.2 North America Retail Pharmacy Market Size
      • 4.1.9.3 North America Online Pharmacy Market Size
    • 4.1.10 North America NSAIDs Volume Market Sales by Distribution Channel Outlook: 2022 - 2034
      • 4.1.10.1 North America Hospital Pharmacy Sales Volume
      • 4.1.10.2 North America Retail Pharmacy Sales Volume
      • 4.1.10.3 North America Online Pharmacy Sales Volume

  • 5.1 Europe NSAIDs Market Outlook
    • 5.1.1 Europe NSAIDs Market Size 2022 - 2034
    • 5.1.2 Europe NSAIDs Volume Market Sales 2022 - 2034
    • 5.1.3 Europe NSAIDs Market Size By Country 2022 - 2034
    • 5.1.4 Europe NSAIDs Volume Market Sales By Country 2022 - 2034
    • 5.1.5 Europe NSAIDs Market Size by End Use Outlook: 2022 - 2034
      • 5.1.5.1 Europe Back Pain Treatment Market Size
      • 5.1.5.2 Europe Osteoarthritis Treatment Market Size
      • 5.1.5.3 Europe Other Disease Treatment Market Size
    • 5.1.6 Europe NSAIDs Volume Market Sales by End Use Outlook: 2022 - 2034
      • 5.1.6.1 Europe Back Pain Treatment Sales Volume
      • 5.1.6.2 Europe Osteoarthritis Treatment Sales Volume
      • 5.1.6.3 Europe Other Disease Treatment Sales Volume
    • 5.1.7 Europe NSAIDs Market Size by Administration Outlook: 2022 - 2034
      • 5.1.7.1 Europe Oral Market Size
      • 5.1.7.2 Europe Topical Market Size
      • 5.1.7.3 Europe Others Market Size
    • 5.1.8 Europe NSAIDs Volume Market Sales by Administration Outlook: 2022 - 2034
      • 5.1.8.1 Europe Oral Sales Volume
      • 5.1.8.2 Europe Topical Sales Volume
      • 5.1.8.3 Europe Others Sales Volume
    • 5.1.9 Europe NSAIDs Market Size by Distribution Channel Outlook: 2022 - 2034
      • 5.1.9.1 Europe Hospital Pharmacy Market Size
      • 5.1.9.2 Europe Retail Pharmacy Market Size
      • 5.1.9.3 Europe Online Pharmacy Market Size
    • 5.1.10 Europe NSAIDs Volume Market Sales by Distribution Channel Outlook: 2022 - 2034
      • 5.1.10.1 Europe Hospital Pharmacy Sales Volume
      • 5.1.10.2 Europe Retail Pharmacy Sales Volume
      • 5.1.10.3 Europe Online Pharmacy Sales Volume

  • 6.1 Asia Pacific NSAIDs Market Outlook
    • 6.1.1 Asia Pacific NSAIDs Market Size 2022 - 2034
    • 6.1.2 Asia Pacific NSAIDs Volume Market Sales 2022 - 2034
    • 6.1.3 Asia Pacific NSAIDs Market Size By Country 2022 - 2034
    • 6.1.4 Asia Pacific NSAIDs Volume Market Sales By Country 2022 - 2034
    • 6.1.5 Asia Pacific NSAIDs Market Size by End Use Outlook: 2022 - 2034
      • 6.1.5.1 Asia Pacific Back Pain Treatment Market Size
      • 6.1.5.2 Asia Pacific Osteoarthritis Treatment Market Size
      • 6.1.5.3 Asia Pacific Other Disease Treatment Market Size
    • 6.1.6 Asia Pacific NSAIDs Volume Market Sales by End Use Outlook: 2022 - 2034
      • 6.1.6.1 Asia Pacific Back Pain Treatment Sales Volume
      • 6.1.6.2 Asia Pacific Osteoarthritis Treatment Sales Volume
      • 6.1.6.3 Asia Pacific Other Disease Treatment Sales Volume
    • 6.1.7 Asia Pacific NSAIDs Market Size by Administration Outlook: 2022 - 2034
      • 6.1.7.1 Asia Pacific Oral Market Size
      • 6.1.7.2 Asia Pacific Topical Market Size
      • 6.1.7.3 Asia Pacific Others Market Size
    • 6.1.8 Asia Pacific NSAIDs Volume Market Sales by Administration Outlook: 2022 - 2034
      • 6.1.8.1 Asia Pacific Oral Sales Volume
      • 6.1.8.2 Asia Pacific Topical Sales Volume
      • 6.1.8.3 Asia Pacific Others Sales Volume
    • 6.1.9 Asia Pacific NSAIDs Market Size by Distribution Channel Outlook: 2022 - 2034
      • 6.1.9.1 Asia Pacific Hospital Pharmacy Market Size
      • 6.1.9.2 Asia Pacific Retail Pharmacy Market Size
      • 6.1.9.3 Asia Pacific Online Pharmacy Market Size
    • 6.1.10 Asia Pacific NSAIDs Volume Market Sales by Distribution Channel Outlook: 2022 - 2034
      • 6.1.10.1 Asia Pacific Hospital Pharmacy Sales Volume
      • 6.1.10.2 Asia Pacific Retail Pharmacy Sales Volume
      • 6.1.10.3 Asia Pacific Online Pharmacy Sales Volume

  • 7.1 South America NSAIDs Market Outlook
    • 7.1.1 South America NSAIDs Market Size 2022 - 2034
    • 7.1.2 South America NSAIDs Volume Market Sales 2022 - 2034
    • 7.1.3 South America NSAIDs Market Size By Country 2022 - 2034
    • 7.1.4 South America NSAIDs Volume Market Sales By Country 2022 - 2034
    • 7.1.5 South America NSAIDs Market Size by End Use Outlook: 2022 - 2034
      • 7.1.5.1 South America Back Pain Treatment Market Size
      • 7.1.5.2 South America Osteoarthritis Treatment Market Size
      • 7.1.5.3 South America Other Disease Treatment Market Size
    • 7.1.6 South America NSAIDs Volume Market Sales by End Use Outlook: 2022 - 2034
      • 7.1.6.1 South America Back Pain Treatment Sales Volume
      • 7.1.6.2 South America Osteoarthritis Treatment Sales Volume
      • 7.1.6.3 South America Other Disease Treatment Sales Volume
    • 7.1.7 South America NSAIDs Market Size by Administration Outlook: 2022 - 2034
      • 7.1.7.1 South America Oral Market Size
      • 7.1.7.2 South America Topical Market Size
      • 7.1.7.3 South America Others Market Size
    • 7.1.8 South America NSAIDs Volume Market Sales by Administration Outlook: 2022 - 2034
      • 7.1.8.1 South America Oral Sales Volume
      • 7.1.8.2 South America Topical Sales Volume
      • 7.1.8.3 South America Others Sales Volume
    • 7.1.9 South America NSAIDs Market Size by Distribution Channel Outlook: 2022 - 2034
      • 7.1.9.1 South America Hospital Pharmacy Market Size
      • 7.1.9.2 South America Retail Pharmacy Market Size
      • 7.1.9.3 South America Online Pharmacy Market Size
    • 7.1.10 South America NSAIDs Volume Market Sales by Distribution Channel Outlook: 2022 - 2034
      • 7.1.10.1 South America Hospital Pharmacy Sales Volume
      • 7.1.10.2 South America Retail Pharmacy Sales Volume
      • 7.1.10.3 South America Online Pharmacy Sales Volume

  • 8.1 Middle East NSAIDs Market Outlook
    • 8.1.1 Middle East NSAIDs Market Size 2022 - 2034
    • 8.1.2 Middle East NSAIDs Volume Market Sales 2022 - 2034
    • 8.1.3 Middle East NSAIDs Market Size By Country 2022 - 2034
    • 8.1.4 Middle East NSAIDs Volume Market Sales By Country 2022 - 2034
    • 8.1.5 Middle East NSAIDs Market Size by End Use Outlook: 2022 - 2034
      • 8.1.5.1 Middle East Back Pain Treatment Market Size
      • 8.1.5.2 Middle East Osteoarthritis Treatment Market Size
      • 8.1.5.3 Middle East Other Disease Treatment Market Size
    • 8.1.6 Middle East NSAIDs Volume Market Sales by End Use Outlook: 2022 - 2034
      • 8.1.6.1 Middle East Back Pain Treatment Sales Volume
      • 8.1.6.2 Middle East Osteoarthritis Treatment Sales Volume
      • 8.1.6.3 Middle East Other Disease Treatment Sales Volume
    • 8.1.7 Middle East NSAIDs Market Size by Administration Outlook: 2022 - 2034
      • 8.1.7.1 Middle East Oral Market Size
      • 8.1.7.2 Middle East Topical Market Size
      • 8.1.7.3 Middle East Others Market Size
    • 8.1.8 Middle East NSAIDs Volume Market Sales by Administration Outlook: 2022 - 2034
      • 8.1.8.1 Middle East Oral Sales Volume
      • 8.1.8.2 Middle East Topical Sales Volume
      • 8.1.8.3 Middle East Others Sales Volume
    • 8.1.9 Middle East NSAIDs Market Size by Distribution Channel Outlook: 2022 - 2034
      • 8.1.9.1 Middle East Hospital Pharmacy Market Size
      • 8.1.9.2 Middle East Retail Pharmacy Market Size
      • 8.1.9.3 Middle East Online Pharmacy Market Size
    • 8.1.10 Middle East NSAIDs Volume Market Sales by Distribution Channel Outlook: 2022 - 2034
      • 8.1.10.1 Middle East Hospital Pharmacy Sales Volume
      • 8.1.10.2 Middle East Retail Pharmacy Sales Volume
      • 8.1.10.3 Middle East Online Pharmacy Sales Volume

  • 9.1 Africa NSAIDs Market Outlook
    • 9.1.1 Africa NSAIDs Market Size 2022 - 2034
    • 9.1.2 Africa NSAIDs Volume Market Sales 2022 - 2034
    • 9.1.3 Africa NSAIDs Market Size By Country 2022 - 2034
    • 9.1.4 Africa NSAIDs Volume Market Sales By Country 2022 - 2034
    • 9.1.5 Africa NSAIDs Market Size by End Use Outlook: 2022 - 2034
      • 9.1.5.1 Africa Back Pain Treatment Market Size
      • 9.1.5.2 Africa Osteoarthritis Treatment Market Size
      • 9.1.5.3 Africa Other Disease Treatment Market Size
    • 9.1.6 Africa NSAIDs Volume Market Sales by End Use Outlook: 2022 - 2034
      • 9.1.6.1 Africa Back Pain Treatment Sales Volume
      • 9.1.6.2 Africa Osteoarthritis Treatment Sales Volume
      • 9.1.6.3 Africa Other Disease Treatment Sales Volume
    • 9.1.7 Africa NSAIDs Market Size by Administration Outlook: 2022 - 2034
      • 9.1.7.1 Africa Oral Market Size
      • 9.1.7.2 Africa Topical Market Size
      • 9.1.7.3 Africa Others Market Size
    • 9.1.8 Africa NSAIDs Volume Market Sales by Administration Outlook: 2022 - 2034
      • 9.1.8.1 Africa Oral Sales Volume
      • 9.1.8.2 Africa Topical Sales Volume
      • 9.1.8.3 Africa Others Sales Volume
    • 9.1.9 Africa NSAIDs Market Size by Distribution Channel Outlook: 2022 - 2034
      • 9.1.9.1 Africa Hospital Pharmacy Market Size
      • 9.1.9.2 Africa Retail Pharmacy Market Size
      • 9.1.9.3 Africa Online Pharmacy Market Size
    • 9.1.10 Africa NSAIDs Volume Market Sales by Distribution Channel Outlook: 2022 - 2034
      • 9.1.10.1 Africa Hospital Pharmacy Sales Volume
      • 9.1.10.2 Africa Retail Pharmacy Sales Volume
      • 9.1.10.3 Africa Online Pharmacy Sales Volume

  • 10.1 Top Competitors Analysis

    • (Subject to Data Availability (Private Players))

      10.1.1 Global NSAIDs Market Revenue and Share by Key Players
    • 10.1.2 Global NSAIDs Market Volume and Share by Key Players
    • 10.1.3 Top Players Ranking 2024
    • 10.1.4 New Product Launch Analysis
    • 10.1.5 Industry Mergers and Acquisition Analysis
  • 10.2 Company Profile (Data Subject to Availability) Sample Format

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.1 Pfizer Inc.
      • 10.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.1.2 Business Overview
      • 10.2.1.3 Financials (Subject to data availability)
      • 10.2.1.4 R&D Investment (Subject to data availability)
      • 10.2.1.5 Product Types Specification
      • 10.2.1.6 Business Strategy
      • 10.2.1.7 Recent Developments
      • 10.2.1.8 Management Change
      • 10.2.1.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.2 Johnson & Johnson
      • 10.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.2.2 Business Overview
      • 10.2.2.3 Financials (Subject to data availability)
      • 10.2.2.4 R&D Investment (Subject to data availability)
      • 10.2.2.5 Product Types Specification
      • 10.2.2.6 Business Strategy
      • 10.2.2.7 Recent Developments
      • 10.2.2.8 Management Change
      • 10.2.2.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.3 Novartis AG
      • 10.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.3.2 Business Overview
      • 10.2.3.3 Financials (Subject to data availability)
      • 10.2.3.4 R&D Investment (Subject to data availability)
      • 10.2.3.5 Product Types Specification
      • 10.2.3.6 Business Strategy
      • 10.2.3.7 Recent Developments
      • 10.2.3.8 Management Change
      • 10.2.3.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.4 GlaxoSmithKline plc
      • 10.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.4.2 Business Overview
      • 10.2.4.3 Financials (Subject to data availability)
      • 10.2.4.4 R&D Investment (Subject to data availability)
      • 10.2.4.5 Product Types Specification
      • 10.2.4.6 Business Strategy
      • 10.2.4.7 Recent Developments
      • 10.2.4.8 Management Change
      • 10.2.4.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.5 Bayer AG
      • 10.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.5.2 Business Overview
      • 10.2.5.3 Financials (Subject to data availability)
      • 10.2.5.4 R&D Investment (Subject to data availability)
      • 10.2.5.5 Product Types Specification
      • 10.2.5.6 Business Strategy
      • 10.2.5.7 Recent Developments
      • 10.2.5.8 Management Change
      • 10.2.5.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.6 Sanofi S.A.
      • 10.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.6.2 Business Overview
      • 10.2.6.3 Financials (Subject to data availability)
      • 10.2.6.4 R&D Investment (Subject to data availability)
      • 10.2.6.5 Product Types Specification
      • 10.2.6.6 Business Strategy
      • 10.2.6.7 Recent Developments
      • 10.2.6.8 Management Change
      • 10.2.6.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.7 Abbott Laboratories
      • 10.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.7.2 Business Overview
      • 10.2.7.3 Financials (Subject to data availability)
      • 10.2.7.4 R&D Investment (Subject to data availability)
      • 10.2.7.5 Product Types Specification
      • 10.2.7.6 Business Strategy
      • 10.2.7.7 Recent Developments
      • 10.2.7.8 Management Change
      • 10.2.7.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.8 Merck & Co.
      • 10.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.8.2 Business Overview
      • 10.2.8.3 Financials (Subject to data availability)
      • 10.2.8.4 R&D Investment (Subject to data availability)
      • 10.2.8.5 Product Types Specification
      • 10.2.8.6 Business Strategy
      • 10.2.8.7 Recent Developments
      • 10.2.8.8 Management Change
      • 10.2.8.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.9 Inc.
      • 10.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.9.2 Business Overview
      • 10.2.9.3 Financials (Subject to data availability)
      • 10.2.9.4 R&D Investment (Subject to data availability)
      • 10.2.9.5 Product Types Specification
      • 10.2.9.6 Business Strategy
      • 10.2.9.7 Recent Developments
      • 10.2.9.8 Management Change
      • 10.2.9.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.10 Amgen Inc.
      • 10.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.10.2 Business Overview
      • 10.2.10.3 Financials (Subject to data availability)
      • 10.2.10.4 R&D Investment (Subject to data availability)
      • 10.2.10.5 Product Types Specification
      • 10.2.10.6 Business Strategy
      • 10.2.10.7 Recent Developments
      • 10.2.10.8 Management Change
      • 10.2.10.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.11 Mylan N.V.
      • 10.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.11.2 Business Overview
      • 10.2.11.3 Financials (Subject to data availability)
      • 10.2.11.4 R&D Investment (Subject to data availability)
      • 10.2.11.5 Product Types Specification
      • 10.2.11.6 Business Strategy
      • 10.2.11.7 Recent Developments
      • 10.2.11.8 Management Change
      • 10.2.11.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.12 Teva Pharmaceutical Industries Ltd.
      • 10.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.12.2 Business Overview
      • 10.2.12.3 Financials (Subject to data availability)
      • 10.2.12.4 R&D Investment (Subject to data availability)
      • 10.2.12.5 Product Types Specification
      • 10.2.12.6 Business Strategy
      • 10.2.12.7 Recent Developments
      • 10.2.12.8 Management Change
      • 10.2.12.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.13 Aurobindo Pharma
      • 10.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.13.2 Business Overview
      • 10.2.13.3 Financials (Subject to data availability)
      • 10.2.13.4 R&D Investment (Subject to data availability)
      • 10.2.13.5 Product Types Specification
      • 10.2.13.6 Business Strategy
      • 10.2.13.7 Recent Developments
      • 10.2.13.8 Management Change
      • 10.2.13.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.14 Cipla Limited
      • 10.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.14.2 Business Overview
      • 10.2.14.3 Financials (Subject to data availability)
      • 10.2.14.4 R&D Investment (Subject to data availability)
      • 10.2.14.5 Product Types Specification
      • 10.2.14.6 Business Strategy
      • 10.2.14.7 Recent Developments
      • 10.2.14.8 Management Change
      • 10.2.14.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.15 Sun Pharmaceutical Industries Ltd.
      • 10.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.15.2 Business Overview
      • 10.2.15.3 Financials (Subject to data availability)
      • 10.2.15.4 R&D Investment (Subject to data availability)
      • 10.2.15.5 Product Types Specification
      • 10.2.15.6 Business Strategy
      • 10.2.15.7 Recent Developments
      • 10.2.15.8 Management Change
      • 10.2.15.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.16 Mallinckrodt Pharmaceuticals
      • 10.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.16.2 Business Overview
      • 10.2.16.3 Financials (Subject to data availability)
      • 10.2.16.4 R&D Investment (Subject to data availability)
      • 10.2.16.5 Product Types Specification
      • 10.2.16.6 Business Strategy
      • 10.2.16.7 Recent Developments
      • 10.2.16.8 Management Change
      • 10.2.16.9 S.W.O.T Analysis

  • 11.1 Market Drivers
  • 11.2 Market Restraints
  • 11.3 Market Trends
  • 11.4 Market Opportunity
  • 11.5 Technological Road Map (Subject to Data Availability)
  • 11.6 Product Life Cycle (Subject to Data Availability)
  • 11.7 Customer and Buyer Behavior Analysis
    • 11.7.1 Consumer Demographics and Target Audience Assessment
    • 11.7.2 Consumer Purchase Behavior and Demand Assessment
    • 11.7.3 Consumer Pricing Dynamics and Affordability Assessment
    • 11.7.4 Digital Consumer Engagement and Online Adoption Analysis
    • 11.7.5 Future Consumption Trends and Demand Evolution Analysis
    • 11.7.6 Enterprise Procurement & Purchasing Behavior Analysis
    • 11.7.7 Buyer Decision-Making & Purchase Influence Assessment
    • 11.7.8 Customer Expectations & Service Experience Evaluation
    • 11.7.9 Vendor Selection & Supplier Preference Analysis
    • 11.7.10 Customer Retention & Loyalty Strategy Assessment
    • 11.7.11 Pricing Sensitivity & Value Perception Analysis
    • 11.7.12 Customer Segmentation & Demand Pattern Analysis
    • 11.7.13 Relationship Management & Strategic Partnership Trends
  • 11.8 Market Attractiveness Analysis
  • 11.9 PESTEL Analysis
    • 11.9.1 Political Factors
    • 11.9.2 Economic Factors
    • 11.9.3 Social Factors
    • 11.9.4 Technological Factors
    • 11.9.5 Legal Factors
    • 11.9.6 Environmental Factors
  • 11.10 Industrial Chain Analysis (Subject to Data Availability)
    • 11.10.1 Industry Chain Analysis
    • 11.10.2 Manufacturing Cost Analysis
    • 11.10.3 Supply Side Analysis
      • 11.10.3.1 Raw Material Analysis
      • 11.10.3.2 Raw Material Procurement Analysis
      • 11.10.3.3 Raw Material Price Trend Analysis
  • 11.11 Porter’s Five Forces Analysis
    • 11.11.1 Bargaining Power of Suppliers
    • 11.11.2 Bargaining Power of Buyers
    • 11.11.3 Threat of New Entrants
    • 11.11.4 Threat of Substitutes
    • 11.11.5 Degree of Competition
  • 11.12 Patent Analysis (Subject to Data Availability)
  • 11.13 ESG Analysis

  • 12.1 Back Pain Treatment
    • 12.1.1 Global NSAIDs Revenue Market Size and Share by Back Pain Treatment 2022 - 2034
    • 12.1.2 Global NSAIDs Volume Market Sales by Back Pain Treatment 2022 - 2034
  • 12.2 Osteoarthritis Treatment
    • 12.2.1 Global NSAIDs Revenue Market Size and Share by Osteoarthritis Treatment 2022 - 2034
    • 12.2.2 Global NSAIDs Volume Market Sales by Osteoarthritis Treatment 2022 - 2034
  • 12.3 Other Disease Treatment
    • 12.3.1 Global NSAIDs Revenue Market Size and Share by Other Disease Treatment 2022 - 2034
    • 12.3.2 Global NSAIDs Volume Market Sales by Other Disease Treatment 2022 - 2034

  • 13.1 Oral
    • 13.1.1 Global NSAIDs Revenue Market Size and Share by Oral 2022 - 2034
    • 13.1.2 Global NSAIDs Volume Market Sales by Oral 2022 - 2034
  • 13.2 Topical
    • 13.2.1 Global NSAIDs Revenue Market Size and Share by Topical 2022 - 2034
    • 13.2.2 Global NSAIDs Volume Market Sales by Topical 2022 - 2034
  • 13.3 Others
    • 13.3.1 Global NSAIDs Revenue Market Size and Share by Others 2022 - 2034
    • 13.3.2 Global NSAIDs Volume Market Sales by Others 2022 - 2034

  • 14.1 Hospital Pharmacy
    • 14.1.1 Global NSAIDs Revenue Market Size and Share by Hospital Pharmacy 2022 - 2034
    • 14.1.2 Global NSAIDs Volume Market Sales by Hospital Pharmacy 2022 - 2034
  • 14.2 Retail Pharmacy
    • 14.2.1 Global NSAIDs Revenue Market Size and Share by Retail Pharmacy 2022 - 2034
    • 14.2.2 Global NSAIDs Volume Market Sales by Retail Pharmacy 2022 - 2034
  • 14.3 Online Pharmacy
    • 14.3.1 Global NSAIDs Revenue Market Size and Share by Online Pharmacy 2022 - 2034
    • 14.3.2 Global NSAIDs Volume Market Sales by Online Pharmacy 2022 - 2034

  • 15.1 Company Gap Assessment Analysis
  • 15.2 Product & Service Portfolio Gap Analysis
  • 15.3 Demand-Supply Imbalance Analysis
  • 15.4 Market Opportunity & Unmet Needs Analysis
  • 15.5 Technology Adoption & Digital Transformation Gap Analysis
  • 15.6 Operational Efficiency & Process Gap Analysis
  • 15.7 Infrastructure & Capacity Gap Analysis
  • 15.8 Geographic Coverage & Distribution Gap Analysis
  • 15.9 Investment Opportunity & Funding Gap Analysis
  • 15.10 Pricing Structure & Margin Gap Analysis
  • 15.11 Innovation & R&D Capability Gap Analysis
  • 15.12 Policy, Compliance & Regulatory Gap Analysis
  • 15.13 Customer Experience & Expectation Gap Analysis
  • 15.14 Future Growth Opportunity Gap Analysis
  • 15.15 Market Accessibility & Penetration Gap Analysis

  • 16.1 Gross Margin Overview and Industry Profitability Trends
  • 16.2 Regional Gross Margin Performance Analysis
  • 16.3 Supply Chain and Distribution Impact on Gross Margins
  • 16.4 Pricing Strategy and Value-Added Margin Assessment
  • 16.5 Key Factors Influencing Gross Margin Variability
  • 16.6 Future Gross Margin Outlook and Profitability Trends

  • 17.1 Key Takeaways

  • Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.

    17.2 Analyst Point of View
  • 17.3 Assumptions and Acronyms

  • 18.1 Primary Data Collection
    • 18.1.1 Steps for Primary Data Collection
      • 18.1.1.1 Identification of KOL
    • 18.1.2 Backward Integration
    • 18.1.3 Forward Integration
    • 18.1.4 How Primary Research Help Us
    • 18.1.5 Modes of Primary Research
  • 18.2 Secondary Research
    • 18.2.1 How Secondary Research Help Us
    • 18.2.2 Sources of Secondary Research
  • 18.3 Data Validation
    • 18.3.1 Data Triangulation
    • 18.3.2 Top Down & Bottom Up Approach
    • 18.3.3 Cross check KOL Responses with Secondary Data
  • 18.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research employs "The Full Truth™" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the NSAIDs Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 16+
Forecast Accuracy (Historical) 94.2%
Report Pages 250+
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about NSAIDs Market

Sources from Pharma & Healthcare Industry

How We Serve You

Three Pillars of Market Intelligence

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the NSAIDs Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the nsaids market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report (250+ pages)
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.